Our study highlights the potential of LAMP1 as a novel biomarker for diagnosing ccRCC patients and predicting their prognosis, while also providing valuable insights into the underlying molecular mechanisms that could guide targeted therapeutic strategies for renal cancer. This evidence concerns the gene LAMP1 and nonpapillary renal cell carcinoma.